Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Fujifilm Holdings America Corporation has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 2 distinct examiners and 2 distinct art units, indicating a diverse review process for the company. This spread suggests that the company's current patent applications are being evaluated in different technical contexts, requiring a broader approach to prosecution than a more concentrated portfolio would necessitate.
BOECKELMAN, JACOB A is the busiest examiner, currently overseeing 1 pending office action. Given that there are 2 pending office actions and 2 distinct examiners, each examiner is responsible for 1 action. This arrangement across 2 distinct art units suggests that the company's current patent challenges are being addressed by separate technical groups. To resolve the 2 pending office actions, practitioners must navigate the specific standards of 2 distinct art units, ensuring that each application is tailored to the expectations of its respective examiner and unit.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BOECKELMAN, JACOB A | 1 | 35.2% | +45.6% |
| BEHARRY, ZANNA MARIA | 1 | 24.7% | +56.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17619096 | METHODS FOR THE PRODUCTION OF MULTIPLE LINEAGES FROM INDUCED PLURIPOTENT STEM CELLS USING CHARGED SURFACES | BEHARRY, ZANNA MARIA | 8d overdue |
| 18545837 | EXTRACELLULAR VESICLE-ENRICHED SECRETOME COMPOSITION DERIVED FROM INDUCED PLURIPOTENT STEM CELL DERIVED-MICROGLIA AND METHODS OF USE THEREOF | BOECKELMAN, JACOB A | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17619096 | METHODS FOR THE PRODUCTION OF MULTIPLE LINEAGES FROM INDUCED PLURIPOTENT STEM CELLS USING CHARGED SURFACES | BEHARRY, ZANNA MARIA | 8d overdue |
| 18545837 | EXTRACELLULAR VESICLE-ENRICHED SECRETOME COMPOSITION DERIVED FROM INDUCED PLURIPOTENT STEM CELL DERIVED-MICROGLIA AND METHODS OF USE THEREOF | BOECKELMAN, JACOB A | — |
| Art Unit | Apps |
|---|---|
| 1655 | 1 |
| 1632 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18545837 | EXTRACELLULAR VESICLE-ENRICHED SECRETOME COMPOSITION DERIVED FROM INDUCED PLURIPOTENT STEM CELL DERIVED-MICROGLIA AND METHODS OF USE THEREOF | BOECKELMAN, JACOB A | 1655 | §102§103§112 | Non-Final OA | — | Pending | Dec 19, 2023 |
| 17619096 | METHODS FOR THE PRODUCTION OF MULTIPLE LINEAGES FROM INDUCED PLURIPOTENT STEM CELLS USING CHARGED SURFACES | BEHARRY, ZANNA MARIA | 1632 | §103§112 | Final Rejection | 8d overdue | Pending | Dec 14, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial